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ABSTRACT 
OBJECTIVE: The objective of this selective EBM review is to determine whether or not 
intranasal oxytocin is an effective treatment for reducing disruptive behavior in individuals with 
Prader-Willi Syndrome. 
 
STUDY DESIGN: This is a systematic review of two randomized controlled crossover trials and 
one randomized controlled pilot study, all of which were double-blind and placebo-controlled. 
All articles were peer-reviewed, written in English and published between 2011 and 2016. 
 
DATA SOURCES: The three articles used in this systematic review were found in PubMed 
based on their relevance to the objective of the study, the inclusion of patient-oriented problems 
and published within the last 10 years.  
 
OUTCOMES MEASURED: The outcomes measured for this review are the individual’s 
disruptive behavior and whether there was an improvement after administering intranasal 
oxytocin. One study used a questionnaire rated by parents of children with Prader-Willi 
Syndrome, another used a developmental behavior checklist version M to rate temper outburst 
and the last study scored disruptive behavior on a grid by a team of psychologists.  
 
RESULTS: Two of the three studies demonstrated no statistically significant improvement in 
disruptive behavior in individuals with Prader-Willi syndrome.6,8 Kuppens et al. with no 
statistical significance demonstrated as group 6-11 years old had a p-value of 0.071 and age 11-
14 with p-value of 0.109.6 Einfeld et al. demonstrated an increase in temper outbursts when a 
higher dose of oxytocin was administered with p-value of 0.01.7 Tauber et al resulted in 
statistically significant reduction in disruptive behavior in the late effect with p-value 0.031 but 
overall, the data documented no significance in the reduction of disruptive behavior.8 
 
CONCLUSIONS: The use of intranasal oxytocin to reduce disruptive behavior is promising, 
however, the current data on the use of intranasal oxytocin to reduce disruptive behavior in 
individuals with PWS is inconclusive. Each study demonstrated a different conclusion on the 
data ranging from increasing disruptive behavior to decreasing disruptive behavior. 
Consequently, more research is needed in order to draw a formal conclusion on the use of 
intranasal oxytocin and its potential effects on behavior in individuals with Prader-Willi 
syndrome. 
 
KEYWORDS: Prader-Willi Syndrome (PWS) and Oxytocin 
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INTRODUCTION: 
 Prader-Willi Syndrome (PWS) is a genetic disorder involving chromosome 15 and the 
hypothalamus. PWS affects appetite, growth, metabolism, cognitive function and behavior with 
typical features including: short stature, decreased muscle tone, incomplete sexual development, 
intellectual disability, and insatiable hunger leading to obesity.1 In PWS, the hypothalamus is 
unable to regulate hunger and satiety but the direct cause as to why this occurs is unknown. The 
etiology of PWS is either a genetic deletion or mutation of chromosome 15 occurring 
spontaneously at or near conception for unknown reasons.2 PWS affects males and females 
equally and occurs in all ethnic groups and geographic regions worldwide without a significant 
commonality among a certain population.1  PWS is estimated to affect 12,000-15,000 individuals 
in the United States and about 350,000 individuals worldwide, making PWS the most common 
genetic cause of obesity.3,4 
PWS is usually diagnosed with a blood test and may be picked up on a well-child exam. 
Very few specialists for PWS exist, meaning their care starts with their Primary Care Provider 
(PCP). PWS takes a team of healthcare professionals, including physician assistants in different 
specialties ranging from mental health to endocrinology. The number of healthcare visits per 
year is unknown but is substantially greater than a patient without PWS. Healthcare visits range 
from 18-150 visits per year and correlate with age, with the most frequent visits per year being 
age 41-64 years.2 The exact annual healthcare cost for an individual with PWS is unknown, 
however, one study reported that the average annual cost per person ranges from $82,321-
$134,395.5 The large number of healthcare visits and expense could be attributed to the lack of 
specialists for PWS and an inability to effectively care for these individuals due to a lack of 
expertise on the condition.  
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PWS is treated in a similar fashion as Autism, in that, the person is treated individually 
based on the needs of their symptoms. Common treatments include Human growth hormone 
(hGH) supplement for short stature, sex hormone therapy to promote sexual maturation, weight 
management, CPAP (continuous positive airway pressure) or BiPAP (bilevel positive airway 
pressure) machine for sleep disorders such as sleep apnea and a psychiatrist or psychologist for 
mental health care.3 
The method of using intranasal oxytocin is being proposed to treat PWS because the 
oxytocin system in PWS patients is dysfunctional and there is currently no standard treatment for 
behavioral problems and hyperphagia in these individuals. Oxytocin is known to affect body 
weight, feeding schedules, and social skills.6 Intranasal oxytocin is thought to positively impact 
and regulate behavior and hyperphagia in PWS and this paper evaluates three different 
randomized controlled trials (RCTs) comparing the efficacy of intranasal oxytocin as a treatment 
to reduce disruptive behavior in those with PWS. 
OBJECTIVE: 
The objective of this selective evidence-based medicine (EBM) review is to determine 
whether or not intranasal oxytocin is an effective treatment for reducing disruptive behavior in 
individuals with Prader-Willi Syndrome. 
METHODS: 
The studies used in this systematic review were researched by the author in both 
Cochrane Library and PubMed. All the studies for this systematic review were located via 
PubMed using keywords “Prader-willi syndrome” and “oxytocin”. To be selected, the article 
must be a randomized, controlled, double-blind study involving individuals with PWS, be peer-
reviewed and published within the last 10 years. In addition, each study must have evaluated 
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patient-oriented outcomes (POEMS) that pertained to the clinical question regarding disruptive 
behavior reduction. Articles were excluded if they did not pertain to the clinical question or if 
their publication date was greater than 10 years old.  
Each article used in this study was published in English in a peer-reviewed journal, one in 
Orphanet Journal of Rare Diseases, one in American Journal of Medical Genetics, and one in 
Clinical Endocrinology.6-8 Of the articles selected, there were two randomized, controlled 
crossover trials and one randomized, controlled pilot study, all of which were double-blind, and 
placebo-controlled. Each study included a population of individuals with PWS with an 
intervention of intranasal oxytocin in comparison to intranasal placebo groups, with at least one -
outcome measurement involving POEMS of disruptive behavior/temper outbursts.6-8 Statistics 
used in these studies include: P-value, Wilcoxon and Mann Whitney test. Table I, seen below, 
summarizes the demographics and characteristics observed in each study.  
Table 1: demographics & characteristics of included studies  
Study Type #pts Age 
(yrs) 
Inclusion 
criteria 
Exclusion 
criteria 
W
/D 
Intervention 
Kuppens6 
(2016) 
Randomized 
controlled 
crossover 
trial 
(double-
blind, 
placebo-
controlled) 
25 6-14 Genetically 
confirmed dx 
of PWS 
Age 6-14 
Social 
behavioral 
problems 
and/or 
preoccupation 
with food 
Were naïve of 
oxytocin 
treatment at 
time of 
enrollment 
Used hGH for 
at least 1 year 
and still 
receiving it  
Severe 
psychiatric 
problems 
Allergic 
reactions/hyper-
sensitivity to 
oxytocin 
Medication to 
reduce 
weight/fat other 
than GH 
Noncooperative 
behavior 
resulting in 
inability to 
comply with 
intranasal 
administration 
0 Syntocinon 
Intranasal 
oxytocin 
dose range 
12 IU -24 IU 
BID 
dependent 
on body 
surface area 
for 4 weeks 
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and or hospital 
visits 
Einfeld7 
(2014) 
Randomized 
controlled 
crossover 
trial 
(double-
blind, 
placebo-
controlled) 
30 12-
29 
PWS 
diagnosis and 
genetic 
subtype 
established 
No known 
hyper-
sensitivity to 
preservatives 
in the nasal 
spray viz 
E216, E218 
and 
chloroubtanol 
hemihydrate 
Mental age 
below 8 years 
old 
8 Intranasal 
Oxytocin  
11 patients 
18+→ 24 IU 
BIDx8weeks 
13-15y/o → 
18 IU BIDx 
8weeks 
18 patients 
18+→ 40 IU 
BIDx8weeks 
13-15y/o → 
32 IU BIDx 
8 weeks 
 
Tauber8 
(2011) 
Randomized 
Controlled 
Pilot Study 
(double-
blind, 
placebo-
controlled) 
24 18-
43 
Genetically 
confirmed 
diagnosis of 
PWS 
Abnormal ECG 
Other severe 
cardiac 
problems 
0 Syntocinon 
Intranasal 
oxytocin, 
single dose 
24 IU 
Saline 
placebo 
 
OUTCOMES MEASURED: 
 In Kuppens et al., the outcomes measured were hyperphagia and social behavior 
including happiness, anger, sadness, conflicts, social interaction, and disruptive behavior.6 The 
outcome that was measured in which this study will focus on is disruptive behavior. In order to 
measure the outcome, the study used an Oxytocin Study Questionnaire completed by parents 
rating child’s behavior from -3 (much less frequent)→+3 (much more frequent) where a decrease 
in 4 points is considered clinically relevant.6 Based on that questionnaire, disruptive behavior 
was then categorized as better, the same or worse from baseline throughout the course of the 
study in both the patients receiving oxytocin and the patients receiving a visually matched 
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placebo.6 These ratings were then used to determine the statistical significance of the outcomes 
measured using the Wilcoxon test and p-values. 
 In Einfeld et al., the primary outcomes measured were hyperphagia/pica and temper 
outbursts.7 Again, the outcome that is the main focus of this systematic review is temper 
outbursts which are descriptive of disruptive behavior. A Developmental Behavior Checklist 
version M (for monitoring) rating behavior from 0-3 on multiple items, including temper 
outburst was utilized.7 This rating was performed by the participant’s caregiver/parent (0= not a 
problem today and 3= major problem today).7 To analyze the statistical significance of the 
outcomes measured, the difference between the rates of change score for items in the two 
treatment conditions, along with p-values were used. 
 In Tauber et al., the primary outcomes addressed were behavior items including isolation 
tendencies, sadness tendencies, depressive tendencies, self-depreciation, self-mutilation, conflicts 
with others, disruptive behavior (including temper outbursts), interests in friendships, interest in 
love affairs, and trust in others.8 This systematic review has a main focus on the disruptive 
behavior/temper outbursts which were measured as an outcome in this study. Tauber et al. used a 
team of psychologists that carefully monitored and scored behaviors on a behavior grid daily.8 
The grid used to measure the outcomes was created by the caregivers, based on routine 
observation of these patients.8 From the scoring, p-values, Mann-Whitney test and Wilcoxon test 
were used to evaluate the statistical significance of the outcomes measured.  
RESULTS: 
 The three studies in this systematic review all addressed the effectiveness of oxytocin to 
reduce disruptive behavior in some capacity. One RCT pilot study and two randomized crossover 
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trials were used. All data presented on this topic was provided as continuous data with p-values 
that were unable to be converted into dichotomous data.  
 Kuppens et al. was a randomized controlled crossover study involving participants 
ranged from age 6-14 years old with a median age of 9.3 years, all children were also receiving 
growth hormone during the study.6 Participants were examined at an outpatient clinic at baseline, 
after 4 weeks and after 8 weeks with behavior being documented at home. This study did not 
involve a washout time period. The study group consisted of 25 children (n=25), 14 boys and 11 
girls all with PWS, all of whom were compliant, completed the study and were included in the 
results of the study.6 The results used in calculating the data were split between two sets of 
groups. Of the original analysis of the entire group, no significant effects of oxytocin on behavior 
were found, however, the results demonstrated beneficial effects on total social behavior in 
younger participants and a sub-analysis was performed on participants age 6-11 (n=17) and those 
11-14 (n=8).6 For this study disruptive behavior is specifically analyzed and based on the 
Wilcoxon Test, no statistical significance was demonstrated as group 6-11 years old had a p-
value of 0.071 and age 11-14 with a p-value of 0.109 ,where p-value < 0.05 is statistically 
significant (see table 2 below). The intranasal oxytocin was not found to have any side effects or 
safety concerns during this study.6 
Table 2: Effects on disruptive behavior of children younger and older than 11 years6 
 Oxytocin Phase Placebo Phase P-value 
Disruptive  
Behavior 
Better Same Worse Better Same Worse  
Age 6-11 
N=17 
4 13 0 1 13 3 0.071 
Age 11-14 
N=8 
0 5 3 2 6 0 0.109 
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 Einfeld et al. was a randomized controlled crossover study involving 30 recruited 
participants age 12-29 with PWS.7 Of the 30 participants 25 participated in phase 1 and 22 
participants completed the crossover (phase 2); leaving 22 participants eligible for analysis 
(n=22).7 The 22 participants were divided into 2 groups, one receiving a low dose of oxytocin 
and the other a high dose oxytocin. Participants temper outburst results were then compared from 
placebo to oxytocin and oxytocin low dose versus high dose. The results included a mean change 
from placebo to oxytocin phases with standard deviation (SD) along with p-values to determine 
statistical significance. The change in temper outburst mean from placebo mean 1.31 (1.23 SD) 
to oxytocin mean 2.16 (1.92 SD) is 0.85 increase in mean showing increase in temper outburst 
with oxytocin administration giving p = 0.023.7 The increase in temper outburst for higher dose 
oxytocin was significant with p = 0.01 overall, but for low dose oxytocin the change was not 
statistically significant with p = 0.746.7 No side effects or safety concerns were reported during 
this study.7 
Table 3: Mean and Standard Deviations for DBM-M temper outbursts7 
 Placebo Oxytocin Oxytocin Low 
dose 
Oxytocin High 
dose 
Temper Outburst 1.31 (1.23) 2.16 (1.92) 1.12 (1.05) 2.62 (2.06) 
Change from 
placebo/baseline 
n/a 0.85 increase 0.19 decrease 1.31 increase 
p-value n/a 0.023 0.746 0.01 
 
Tauber et al. was a randomized controlled pilot study involving 24 adults with PWS age 
18-43 years old.8 Of the 24 participants, 16 were female and 8 were male with a median age of 
28.5 years.8 The study was conducted in a dedicated PWS center where patients are regularly 
admitted for one month and live in a controlled environment.8 Patients were put into pairs of the 
same gender and same IQ range and given a single dose of either oxytocin (OT) or placebo in a 
double-blind randomization. The study took place over the course of three series of admissions.8 
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Results were reported in mean change from pre-administration, early effect (the half day 
following administration) and late effect (2 days following administration) along with a mean 
change in behavioral scores analyzed with Mann Whitney and Wilcoxon tests. Results for 
disruptive behavior in the late effect group were statistically significant with p = 0.031 and the 
pre-post difference was statistically significant for the oxytocin group with p = 0.011.8 Pre-
administration placebo group had mean scores -0.0361 + 0.354, OT -0.431 + 0.344 with p-value 
0.744 (Table 4).8 Early effect mean scores were placebo with -0.250 + 0.452 and OT with            
-.167 + 0.389 with p-value 0.623; late effect mean scores were placebo with -0.306 + 0.382 and 
OT with -0.042 + 0.144 with p-value 0.031 (Table 4).8 The change in mean from pre-post 
disruptive behavior scores are as follows; placebo mean 0.056 (0.457 SD) with p = 0.812, OT 
group mean 0.389 (0.385SD) with p = 0.011 and OT versus placebo Wilcoxon p-value of 0.070 
(Table 5).8 No side effects or safety concerns were reported during this study. 
Table 4: Mean disruptive behavior scores pre-and post-administration8 
Disruptive Behavior Placebo Group Oxytocin Group P-value 
Pre-administration -0.361 + 0.354 -0.431 + 0.344 0.744 
Early effect -0.250 + 0.452 -0.167 + 0.389 0.623 
Late effect -0.306 + 0.382 -0.042 + 0.144 0.031 
 
Table 5: Pre-post behavioral score mean differences8 
 Placebo Group Oxytocin Group Oxytocin vs. Placebo 
Mean (SD) 0.056 (0.457) 0.389 (0.385) n/a 
P-value (Mann-
Whitney) 
0.812 0.011 n/a 
P-value (Wilcoxon) n/a n/a 0.070 
 
DISCUSSIONS: 
This review examines two randomized, controlled crossover trials and one randomized, 
controlled pilot study, all of which are double-blind, and placebo-controlled. Kuppens et al. 
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evaluated only adults, Tauber et al. evaluated only children and Einfeld et al. evaluated both 
adults and children. This reveals an interesting dynamic; although individuals with PWS are 
known to have disruptive behavior, it is possible that after time, some actions have become 
irreversible habit versus redirectable behavior leading to the hypothesis that oxytocin may be 
more beneficial with earlier intervention. In the studies being reviewed, the patients, clinicians 
and study workers were kept blind and all who entered the trial were accounted for. Of the 
studies, Kuppens et al. had a patient who was on levothyroxine, one patient on citalopram and 
one patient on aripiprazole, all of which may impact the effects of oxytocin on disruptive 
behavior.6 In Einfeld et al. 5 patients were diagnosed with anxiety, 3 with depression and 1 with 
schizophrenia which may skew the results of the effectiveness of oxytocin at reducing disruptive 
behavior; however, the results in this study were measured from the individual’s own baseline, 
lessening the likelihood that the results could be skewed.7 Tauber et al. had a similar issue in that 
4 patients in the OT group and 3 in the placebo group were receiving psychotropic medications 
while involved in the study, again potentially affecting the results.8 Although these are 
weaknesses of the studies, there is currently no effective, consistent treatment plan in place for 
individuals with PWS to decrease disruptive behavior and the population of study candidates is 
too small for an adequate sample size.  
Tauber et al. is the only study in which follow-up does not appear to be long enough. The 
participants were followed two days prior to, and 2 days after, administration of oxytocin; there 
may have been change in behavior outside of the follow up period.8 However, these individuals 
were regularly seen and evaluated by staff and it is much more likely that the psychologist team 
would have picked up on even subtle differences over the 4 day total time period. 
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Einfeld et al. was the only study to have withdrawals and loss to follow up. Of the initial 
number beginning the study, 5 individuals never received the initial phase for personal reasons or 
relocation and 3 were lost to follow up after phase 1.7 This did exclude the participants from final 
data analysis, however, the final sample size remained adequate at 22 participants.  
There appears to be no standardized and commonly accepted rating scale for evaluating 
disruptive behavior, let alone the effects of oxytocin in decreasing it. The evaluation in all 
studies was subjective. In some instances, the disruptive behavior increased but, were the 
increases in frequency, duration, intensity or some combination thereof? This is compounded by 
the size of the studies. PWS is not a common condition, so having an adequate sample size in 
one location presents barriers.  
Currently, the intranasal form of oxytocin is not FDA approved; however, it is available 
in Europe.9 Due to the lack of FDA approval, intranasal oxytocin is not able to be covered by 
insurance in the United States. There are several sellers of the product for research purposes, but 
regulations do not exist, making an unreliable medication. Oxytocin is available in the United 
States in intramuscular (IM) and intravenous (IV) formulations, but these were not the forms 
administered in this study. The IM and IV forms carry with them cardiovascular effects, 
antidiuretic effects, and potential maternal death.10 Due to these potential negative effects, 
Tauber et al. excluded individuals from their study if they had an abnormal electrocardiogram.8  
 Limitations in searching for articles included the small number of studies on PWS in 
general, the number of studies conducted using oxytocin, and finding studies that specifically 
used intranasal oxytocin. There are few studies on PWS and even fewer on intranasal oxytocin 
with individuals who have PWS. This led to a selection of studies with a wide range of ages and 
dosages of oxytocin. 
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 Limitations of the studies used included the wide range of dosing, lack of plasma levels 
of oxytocin obtained. In addition, the studies include individuals with PWS without regard to 
whether the PWS was a chromosomal deletion or mutation. Although the participants were 
specified to have deletions or mutations, there was an inability to separate out the groups and 
maintain an adequate sample size for data evaluation.  
CONCLUSION: 
 Research on the use of intranasal oxytocin to reduce disruptive behavior is promising, 
however, the current data on the use of intranasal oxytocin to reduce disruptive behavior in 
individuals with PWS in this systematic review is inconclusive. All three of the studies in this 
review provide conflicting data on whether or not intranasal oxytocin decreased disruptive 
behavior. Einfeld et al even found an increase in disruptive behavior in part of the data analysis.7 
Further studies are needed to discover a more concrete and significant answer to the question this 
review set out to ascertain. Due to some of the flaws of these studies, future studies need a more 
congruent population age, a longer duration of treatment and would benefit from the separation 
of individuals with gene deletion versus mutation. Based on the results of these studies, it would 
be warranted to try and study the effects of oxytocin on younger individuals with PWS and 
measure the outcomes of disruptive behavior over a prolonged period of time to analyze if the 
earlier initiation of oxytocin may decrease the development of some disruptive behaviors 
altogether, as well as provide intervention before the number of oxytocin receptors begin to 
decrease. As a result of the few medical interventions available for PWS patients, a new 
intervention to aid in the management of disruptive behaviors and potentially hyperphagia could 
greatly impact these individuals lives. The only way to discover such an intervention is to 
continue to research potential solutions.
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